• Flumequine: Applied DNA Topoisomerase II Inhibitor Workflows

  2026-07-09

  Flumequine empowers DNA replication and drug response studies with precision, owing to its robust inhibition of topoisomerase II and reliable solubility in DMSO. Explore advanced setup strategies, in vitro protocol optimizations, and troubleshooting guidance that set Flumequine apart in cancer and antibiotic resistance research.

• Resiniferatoxin (RTX): Strategic Translation for Pain & Immu

  2026-07-08

  This thought-leadership article explores the dual mechanistic and translational potential of Resiniferatoxin (RTX) as an ultra-potent TRPV1 agonist. Blending recent immunopharmacology evidence with actionable protocol guidance, it highlights RTX's unique capacity for targeted sensory neuron inactivation, addresses emerging immune considerations, and offers a strategic outlook for researchers navigating pain, inflammation, and cross-domain therapeutic frontiers.

• Host CBS Regulates Inflammation in S. aureus-Induced Mastiti

  2026-07-08

  This study reveals that host-derived cystathionine-β-synthase (CBS) plays a crucial role in balancing inflammation and tissue integrity during Staphylococcus aureus-induced udder infection. The findings highlight CBS as a key modulator of mammary immune responses, offering potential new targets for managing mastitis and related infectious diseases.

• Early Pheromone Exposure Drives Neurodegeneration in C. eleg

  2026-07-07

  Peng et al. (2023) uncover how early-life pheromone perception in C. elegans profoundly remodels neurodevelopment and accelerates adult neurodegeneration via glutamatergic and neuropeptide signaling pathways. Their findings provide mechanistic insight into how environmental chemical cues can modulate neural aging, with implications for understanding environmental contributions to neurodegenerative diseases.

• JZL184: Selective Monoacylglycerol Lipase Inhibitor for Endo

  2026-07-07

  JZL184 is a potent, selective monoacylglycerol lipase inhibitor that elevates brain 2-arachidonoylglycerol (2-AG) levels to modulate endocannabinoid signaling. Its mechanism involves CB1 receptor-mediated pathways, supporting neuropharmacology and pain research with reliable, verifiable experimental benchmarks.

• AG-120 (Ivosidenib): Optimizing IDH1-Mutant AML Research Wor

  2026-07-06

  AG-120 (Ivosidenib) enables precise 2-hydroxyglutarate reduction and myeloid differentiation in IDH1-mutant AML models. This article delivers advanced protocol guidance, actionable troubleshooting, and strategic integration of recent metabolic rewiring insights for researchers seeking translational impact.

• AG-120 (Ivosidenib): Redefining Mutant IDH1 Inhibition & 2-H

  2026-07-06

  Discover how AG-120 (Ivosidenib) achieves precise 2-hydroxyglutarate reduction in mutant IDH1-driven malignancies. This article uniquely dissects its molecular mechanism, translational assay strategies, and the evolving landscape of metabolic rewiring in AML research.

• Moxifloxacin: Fluoroquinolone Antibiotic for Advanced Resear

  2026-07-05

  Harness Moxifloxacin's precision as a fluoroquinolone antibiotic to interrogate bacterial DNA processes, probe cytotoxicity in mammalian cells, and dissect metabolic responses in vivo. Explore experimental workflows, troubleshooting strategies, and the latest mechanistic insights to elevate your antibiotic toxicity and proliferation studies.

• ISR Inhibition Prevents Forgetting and Corrects Epileptic Me

  2026-07-04

  This study reveals that activation of the integrated stress response (ISR) drives both natural and accelerated forgetting of established memories in mice. Pharmacological inhibition of the ISR with ISRIB (trans-isomer) not only prevents physiological memory decay but also reverses seizure-induced accelerated forgetting, highlighting a novel mechanistic link between ISR activity and memory maintenance.

• Oteseconazole (VT-1161): Applied Workflows for Candida Inhib

  2026-07-03

  Oteseconazole (VT-1161) offers unrivaled selectivity and potency for antifungal research, especially when targeting fluconazole-resistant Candida. This guide details streamlined experimental workflows, troubleshooting, and protocol enhancements that empower researchers to maximize translational relevance and reproducibility.

• GLT-1 Upregulation Attenuates TBI via CB1-CREB Pathway Inhib

  2026-07-03

  This study demonstrates that enhancing GLT-1 expression in mice after traumatic brain injury (TBI) reduces neuronal apoptosis and cognitive deficits by inhibiting the CB1-CREB signaling pathway. The findings clarify the mechanistic link between endocannabinoid signaling, astrocytic glutamate transporter regulation, and neuronal survival, highlighting new directions for targeted TBI intervention.

• EdU Imaging Kits (Cy3): Precision S-Phase Cell Proliferation

  2026-07-02

  APExBIO's EdU Imaging Kits (Cy3) deliver sensitive, denaturation-free detection of DNA synthesis, enabling robust quantification of cell proliferation across diverse experimental models. Leveraging click chemistry and Cy3 fluorescence, this kit outperforms traditional BrdU assays in sensitivity, workflow speed, and preservation of cellular architecture.

• CD44-Driven Metabolic Rewiring in IDH-Mutant Leukemia: Impli

  2026-07-02

  A recent study uncovers how CD44-mediated metabolic rewiring sustains NADPH generation and (R)-2-hydroxyglutarate production in IDH-mutant leukemia. The work reveals a combinatorial vulnerability—simultaneous inhibition of CD44 and mutant IDH1—offering new strategies to overcome resistance in AML.

• Z-WEHD-FMK: Precision Caspase Inhibition for Inflammation Re

  2026-07-01

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) empowers researchers to dissect caspase-driven inflammation and cell death with exceptional specificity and workflow flexibility. This article highlights strategic experimental setups, protocol optimizations, and troubleshooting tips that set this irreversible, cell-permeable inhibitor apart for advanced apoptosis and infectious disease research.

• Screening MMV Compounds for Antifungal Activity Against Cand

  2026-07-01

  The referenced study systematically screened MMV Pandemic Response Box compounds for activity against multidrug-resistant bacterial and fungal clinical isolates, including Candida species. Its findings highlight several promising antifungal agents and provide critical MIC/MFC data, supporting further research into new treatments for drug-resistant fungal infections.

555 records 12/37 page Previous Next First page 上5页 1112131415 下5页 Last page